G. Mason Morfit, Partner, VALUEACT CAPITAL

G. Mason Morfit


G. Mason Morfit is one of seven investment partners at ValueAct Capital, a governance-oriented investment fund with approximately $5 billion in assets under management. ValueAct Capital invests in a concentrated number of small and mid-cap US equities and usually works actively with its portfolio companies on selecting their executive teams, developing their business strategies, optimizing their capital structures and executing mergers & acquisitions. The partners at ValueAct Capital have served on the Boards of Directors of 27 public companies. The firm also has the flexibility to execute going-private transactions for 100% control in select circumstances. Mr. Morfit has led investments in Autodesk Inc., Catalina Marketing Corp., Invitrogen Corp., Applied Biosystems Inc., Solexa Inc., Chiron Corp., Valeant Pharmaceuticals International and Advanced Medical Optics, Inc. Mr. Morfit is a director of Valeant Pharmaceuticals International (NYSE: VRX) and Immucor, Inc. (NASDAQ: BULD). The innovative executive compensation structure he designed as Chairman of the Compensation Committee of Valeant Pharmaceuticals was featured in the Wall St. Journal and several academic papers. He is a former director of Advanced Medical Optics (NYSE: EYE), Solexa, Inc. (NASDQ: SLXA) and MSD Performance, Inc. Prior to ValueAct Capital, Mr. Morfit worked in equity research for Credit Suisse First Boston’s health care group covering the managed care industry. He has an AB from Princeton University and is a CFA Charterholder. He has lectured on issues of corporate governance and executive compensation at Stanford Law School’s Director’s College, the Graduate School of Business at Stanford University, and the Haas School of Business at the University of California Berkeley.